Patents by Inventor Keith Jendza

Keith Jendza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20240140959
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 30, 2023
    Publication date: May 2, 2024
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James Anthony NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11820778
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: November 21, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20230212139
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11548865
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 10, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20220411435
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: August 8, 2022
    Publication date: December 29, 2022
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11485742
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: November 1, 2022
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210130365
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 6, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210107889
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 15, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
    Patent number: 9676728
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: June 13, 2017
    Assignee: Novartis AG
    Inventors: Christopher Adams, Takeru Ehara, Keith Jendza, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Nello Mainolfi, James Powers, Michael Serrano-Wu, Chun Zhang
  • 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF
    Publication number: 20160311779
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 29, 2014
    Publication date: October 27, 2016
    Applicant: NOVARTIS AG
    Inventors: Christopher ADAMS, Takeru EHARA, Keith JENDZA, Nan JI, Toshio KAWANAMI, Nello MAINOLFI, James J. POWERS, Michael SERRANO-WU, Chun ZHANG, Rajeshri Ganesh KARKI
  • Complement factor B inhibitors and uses there of
    Patent number: 9475806
    Abstract: The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 25, 2016
    Assignee: Novartis AG
    Inventors: Christopher Michael Adams, Charles Babu, Michael Paul Capparelli, Jian Ding, Takeru Ehara, Keith Jendza, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Liang Xue, Nello Mainolfi, James J. Powers, Michael H. Serrano-Wu, Chun Zhang
  • Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof
    Publication number: 20160145247
    Abstract: The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 26, 2016
    Applicant: NOVARTIS AG
    Inventors: David B. BELANGER, Stefanie FLOHR, Christine Fang GELIN, Keith JENDZA, Nan JI, Donglei LIU, Edwige Lilliane Jeanne LORTHIOIS, Rakeshri Ganesh KARKI, Nello MAINOLFI, James J. POWERS, Stefan Andreas RANDL, Olivier ROGEL, Anna VULPETTI, Taeyoung YOON
  • Complement Factor B inhibitors and uses there of
    Publication number: 20160024079
    Abstract: The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Applicant: NOVARTIS AG
    Inventors: Christopher Michael ADAMS, Charles BABU, Michael Paul CAPPARELLI, Jian DING, Takeru EHARA, Keith JENDZA, Nan JI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Liang XUE, Nello MAINOLFI, James J. POWERS, Michael H. SERRANO-WU, Chun ZHANG
  • Dual-acting benzoimidazole antihypertensive agents
    Patent number: 9198899
    Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: December 1, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul Allegretti, Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • Dual-acting antihypertensive agents
    Patent number: 9150514
    Abstract: The invention is directed to methods for treating hypertension or heart failure using compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. In particular embodiments, the invention uses compounds having formula IIIa, IVa, Va: These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 6, 2015
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • Complement pathway modulators and uses thereof
    Publication number: 20150250767
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 19, 2015
    Publication date: September 10, 2015
    Applicant: NOVARTIS AG
    Inventors: Christopher Michael ADAMS, Charles BABU, Michael Paul CAPPARELLI, Jian DING, Takeru EHARA, Keith JENDZA, Nan JI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Liang XUE, Nello MAINOLFI, James J. POWERS, Michael H. SERRANO-WU, Chun ZHANG
  • Complement pathway modulators and uses thereof
    Patent number: 9056874
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 16, 2015
    Assignee: NOVARTIS AG
    Inventors: Christopher Michael Adams, Charles Babu, Michael Paul Capparelli, Jian Ding, Takeru Ehara, Keith Jendza, Nan Ji, Rajeshri Ganesh Karki, Toshio Kawanami, Liang Xue, Nello Mainolfi, James J. Powers, Michael H. Serrano-Wu, Chun Zhang
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    Publication number: 20150065543
    Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: October 23, 2014
    Publication date: March 5, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity
    Patent number: 8895755
    Abstract: The invention is directed to intermediates for preparing compounds having the formula: wherein: Ar, X, R3 ,and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: November 25, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • Dual-acting antihypertensive agents
    Patent number: 8735625
    Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 27, 2014
    Assignee: Theravance, Inc.
    Inventors: Seok-ki Choi, Paul R. Fatheree, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Vivek Sasikumar